Novartis' canakinumab gets an FDA rejection, but it raises guidance anyway

18th October 2018 Uncategorised 0

Novartis is raising its 2018 sales outlook, but canakinumab won’t help it hit the new target—at least not in the cardiovascular sales department.

More: Novartis' canakinumab gets an FDA rejection, but it raises guidance anyway
Source: fierce